EpiCast Report: Myelofibrosis – Epidemiology Forecast to 2025
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
This report provides an overview of the risk factors, comorbidities, and the global and historical trends for myelofibrosis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of myelofibrosis, PMF, PET MF and PPV MF based on county-specific studies published in peer-reviewed journals. The diagnosed incident cases of PMF are further segmented by sex, age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years), mutations, and the international prognostic scoring system (IPSS) risk categorization. The diagnosed prevalent cases of PMF are further segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years). GlobalData epidemiologists also provide sex-specific diagnosed incident and diagnosed prevalent cases of PET MF and PPV MF in the 7MM for the forecast period.
In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of myelofibrosis (sum of the diagnosed incident cases of PMF and SMF) will increase from 3,791 cases in 2015 to 4,378 cases in 2025, at an Annual Growth Rate (AGR) of 1.55%. The US will have the highest number of diagnosed incident cases of myelofibrosis among the 7MM throughout the forecast period, while Japan will have the lowest.
In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of myelofibrosis will increase from 27,896 cases in 2015 to 32,030 cases in 2025, at an AGR of 1.48%. The US will have the highest number of diagnosed prevalent cases of myelofibrosis among the 7MM throughout the forecast period, while Japan will have the lowest.
GlobalData's forecast is strengthened by the use of peer-reviewed, country-specific publications, which provided the diagnosed incidence and diagnosed prevalence data for PMF, PET MF, and PPV MF in each market. In addition, to improve the comparability of the forecast diagnosed incident and diagnosed prevalent cases of PMF, PET MF, and PPV MF across markets, GlobalData epidemiologists used sources that provided uniform diagnostic criteria for these subcategories.
Scope
The Myelofibrosis EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of myelofibrosis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of myelofibrosis, primary myelofibrosis (PMF), post-essential thrombocytosis myelofibrosis (PET MF) and post-polycythemia vera myelofibrosis (PPV MF). Detailed segmentations of myelofibrosis are also provided.
The myelofibrosis epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.